Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

253 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
RLS/TP/2010/07, CTRI/2011/12/002232: To study the effects of two drugs, R-TPR-017 and Mabthera® (Ristova®) in cancer patients (Non-Hodgkin’s Lymphoma)

Recruiting
3
105
RestOfWorld
Rituximab code named R-TPR-017
Reliance Life Sciences Pvt Ltd , Reliance Life Sciences Pvt Ltd
Non-Hodgkins lymphoma
 
 
ACTRN12610000445077: An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).

Active, not recruiting
3
436
 
Cephalon Inc, Cephalon Inc
Non-Hodgkin's Lymphoma
 
 
CTRI/2012/03/002502: A study of Rituximab in patients with Non Hodgkins Lymphoma a type of cancer

Recruiting
3
100
India
Mabtas (rituximab biosimilar)
Intas
NHL
 
 
BCD020a: A Study of the Efficacy and Safety of Rituximab bio similar study in Subjects With CD20-positive indolent non-Hodgkin lymphoma

Completed
3
92
India, Russian Federation, Ukraine
BCD-020 (rituximab biosimilar)
Biocad
NHL
 
 
rituximabHet: A clinical trial to study the effects of Rituximab injection (Hetero) in Indian patients suffering from varieties of Non-Hodgkins Lymphoma

Recruiting
3
150
India
rituximab biosimilar - Hetero
Hetero Drugs Limited
Non-Hodgkins Lymphoma
 
 
NCT00317096: FCM Versus R-FCM Followed by R-Maintenance or Observation Only

Active, not recruiting
3
319
Europe
FCM, R-FCM, rituximab maintenance, observation only
Ludwig-Maximilians - University of Munich
Lymphoma, Follicular, Lymphoma, Low-Grade, Lymphoma, Intermediate-Grade
06/01
06/21
2004-002197-34: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma

Ongoing
3
1080
Europe
Mabthera, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Solution for infusion, Solution for injection, Tablet
University College London
Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
 
 
2005-005375-15: Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation

Ongoing
3
570
Europe
Mabthera, ENDOXAN, Adriablastine, Vincrisin, Fludara, Medrol, Solu-Medrol, Ro45 2994, Concentrate for solution for infusion, Powder for solution for injection, Solution for injection, Powder and solvent for solution for injection, Tablet
GELA
Mantle cell lymphoma
 
 
2007-003910-33: Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO)

Ongoing
3
60
Europe
Concentrate for solution for infusion, Powder and solvent for solution for injection, MABTHERA, SOLUMEDROL
OSPEDALE MAGGIORE DI MILANO (IRCCS)
Thyroid associeted ophthalmopathy.
 
 
2009-017279-77: Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+ Phase III randomisée multicentrique évaluant la non infériorité d’un traitement adapté à la réponse précoce au morphoTEP par rapport à un traitement standard pour les patients de 18 à 80 ans atteints d’un lymphome malin non hodgkinien B diffus à grandes cellules CD 20 + de faible risque (IPI aa=0)

Ongoing
3
650
Europe
rituximab, Prednisone, Doxorubicine, Cyclophosphamide, Vincristine, G-CSF, Concentrate for solution for infusion, Tablet, Solution for injection, Powder for injection, Unknown (not supplied)
LYSARC, INCa
Patient with Diffuse Large B cells with IPI=0 not previously treated, Patient with Diffuse Large B cells with IPI=0 not previously treated, Diseases [C] - Cancer [C04]
 
 
SWOG S0016, NCT00006721: S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Checkmark P3 data
Dec 2012 - Dec 2012: P3 data
Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Checkmark P3 data in FL
More
Active, not recruiting
3
571
US
rituximab, rituxan, cyclophosphamide, cytoxan, doxorubicin, adriamycin, prednisone, steroid, vincristine, oncovin, tositumomab
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer and Leukemia Group B, Eastern Cooperative Oncology Group
Lymphoma
09/11
03/25
NCT00468377: Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFα Therapies

Active, not recruiting
3
341
US
Rituximab
Hoffmann-La Roche, Genentech
Arthritis, Rheumatoid
12/11
10/14
2011-003539-68: COMPARAISON D'UN TRAITEMENT PREDNISONE + CYCLOPHOSPHAMIDE VERSUS PREDNISONE + RITUXIMAB CHEZ DES PATIENTS ATTEINTS D'HEMOPHILIE ACQUISE

Not yet recruiting
3
164
Europe
Solution for infusion, MabThera
CHU-HOPITAUX DE ROUEN, Ministère de la Recherche et de l'Enseignement supérieur
Hémophilie acquise, Hémophilie acquise, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-006001-10: Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response Valutazione di efficacia di Rituximab al dosaggio di 500mg e.v., 2 infusioni a distanza di 2 settimane, in confronto al dosaggio standard di 1000mg e.v., 2 infusioni a distanza di 2 settimane nel mantenimento della buona risposta clinica in pazienti affetti da artrite reumatoide, gia' trattati con Rituximab al dosaggio standard per almeno 2 cicli

Ongoing
3
48
Europe
Injection, MABTHERA*EV 1FL 50ML 500MG
A.O. UNIVERSITARIA INTEGRATA DI VERONA, Reparto Reumatologia
Rheumatoid arthritis Artrite reumatoide, Rheumatoid arthritis Artrite reumatoide, Diseases [C] - Immune System Diseases [C20]
 
 
2011-006115-59: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)" "Trial controllato randomizzato Rituximab Versus steroide e ciclofosfamide nel trattamento della nefropatia membranosa idiopatica (IMN)"

Ongoing
3
70
Europe
Solution for injection, Solution for infusion, Tablet, Coated tablet, MABTHERA*EV 1FL 50ML 500MG, URBASON*IM EV 1F 250MG+1F 5ML, MEDROL*10CPR DIV 4MG, ENDOXAN BAXTER*50CPR RIV 50MG
AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA, Azienda Spedali Civili di Brescia
MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp La glomerulonefrite membranosa idiopatica è una malattia autoimmune, e potrebbe esser scatenata da specifici anticorpi diretti contro proteine podocitarie e recettori dei podociti che vengono riconosciuti come antigeni, inclusi i recettori M-type fosfolipasi-2, Aldoso-reduttasi e Superossido manganese dismutasi. Il ruolo chiave della formazione di anticorpi IgG nella patogenesi di IMN suggerisce che l, A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) Trial controllato randomizzato Rituximab Versus steroide e ciclofosfamide nel trattamento della nefropatia membranosa idiopatica (IMN), Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
ACTRN12607000112460: Radiotherapy versus radiotherapy plus chemotherapy in early stage follicular lymphoma

Active, not recruiting
3
150
 
Michael MacManus, Cancer Council Victoria, AMGEN
Stage I-II low grade follicular lymphoma
 
 
2011-000221-68: Etude multicentrique randomisée évaluant l’intérêt du Rituximab pour le traitement des glomérulonéphrites extra membraneuses idiopathiques

Ongoing
3
80
Europe
Mabthera, Concentrate for solution for injection, Mabthera
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Glomérulonéphrite extra-membraneuse
 
 
ChiCTR-ONC-12002442: Clinical study of chemoimmunotherapy with fresh frozen plasma, high dose methylprednisolone and rituximab for ultra-high risk chronic lymphocytic leukemia

Completed
3
100
 
FFP+HDMP+Rituximab
Jiangsu Province Hospital; Level of the institution：, Investigator-sponsored
ultra-high risk chronic lymphocytic leukemia
 
 
RESORT, NCT00075946: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Checkmark P3 subgroup data -ASCO
Jun 2012 - Jun 2012: P3 subgroup data -ASCO
Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Completed
3
545
US
rituximab
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Lymphoma
09/13
08/21
ChiCTR-TRC-12002256: Randomized controlled trial of GemOx+/-R regimen in first-line treatment of elderly aggressive B cell lymphoma

Completed
3
100
 
GemOx+Rituximab ;GemOx
JiangSu Province Hospital; JiangSu Province Hospital, investigator-sponsored
Aggressive B cell lymphoma
 
 
CRUK-2004-001621-16, NCT00112931 / 2004-001621-16: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Checkmark P3 data
Jun 2011 - Jun 2011: P3 data
Checkmark P3 data
Dec 2010 - Dec 2010: P3 data
Completed
3
462
Europe, RoW
rituximab, No treatment
University College, London, Cancer Research UK, Roche Pharma AG
Lymphoma
03/14
09/23
ACTRN12611000085976: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

Active, not recruiting
3
80
 
Australasian Leukaemia and Lymphoma Group, GELA, Australasian Leukaemia and Lymphoma Group, Celgene Global
Diffuse large B cell lymphoma (DLBCL) in elderly patients
 
 
2009-017401-11: Comparaison de la radiothérapie multichamps et du rituximab IV dans le traitement des lymphomes B cutanés indolents à lésions multiples ou récidivantes.

Ongoing
3
125
Europe
Concentrate for solution for infusion, MABTHERA
Centre Hospitalier Universitaire de Reims
Lymphomes B cutanés primitifs indolents (c'est-à-dire de type centro-folliculaire ou de la zone marginale) à lésions cutanées multiples ou récidivantes.
 
 
ACTRN12612001045808: A Phase 3 open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (ALLG NHL27)

Active, not recruiting
3
1000
 
The Lymphoma academic research organisation, Australasian Leukaemia and Lymphoma Group
follicular lymphoma
 
 
2014-003529-16: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology

Ongoing
3
219
Europe
MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel
Joint Research & Development Office (QMUL), Medical Research Council, Arthritis Research UK
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2004-001756-36: A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab (Mabthéra® ) after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy.

Ongoing
3
600
Europe
Mabthera, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Fludarabine, Mitoxantrone, Chlorambucil, R, Mabthera, Mabthera
LYSA (The Lymphoma Study Association), GELA (Groupe d\'Etude du Lymphome de l\'Adulte), GELA(RC), LYSARC, , F.Hoffmann-la Roche Ltd.
Advanced follicular lymphoma
 
 
2006-005174-42: Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma

Ongoing
3
460
Europe
prednisone, cyclophosphamide, doxorubicin, vincristine, Neulasta, Neulasta, Mabthera, Neulasta, Mabthera
HOVON Foundation, HOVON Foundation, Roche Nederland B.V.,
diffuse large B-cell lymphoma
 
 
2007-003166-18: Tolérance et efficacité du Rituximab dans le syndrome du Sjögren

Ongoing
3
120
Europe
Mabthera, Mabthera
CHU de Brest
Etude de l\'efficacité du Rituximab pour le traitement du syndrome de Sjögren
 
 
2006-005640-81: A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:

Ongoing
3
60
Europe
Mabthera, Methylprednisolone, Rituximab, Mabthera, Methylprednisolone, Mabthera, Methylprednisolone
University of Leeds
Rheumatoid arthritis
 
 
2007-003213-13: Impact d\'un traitement par le rituximab sur l\'évolution des rejets aigus humoraux après transplantation rénale

Ongoing
3
64
Europe
MabThera, MabThera 500mg, MabThera 100mg, MabThera 500mg, MabThera 100mg
CHRU-Tours
rejet aigu humoral (RAH) après transplantation rénale
 
 
2008-002846-51: Etude de l\'efficacité du Rituximab versus Azathioprine en traitement d\'entretien au cours des vascularites associées aux ANCA : Etude prospective, multicentrique, contrôlée, randomisée

Ongoing
3
112
Europe
Mabthera, AZATHIOPRINE, Mabthera, AZATHIOPRINE, Mabthera, AZATHIOPRINE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Patients atteints de vascularites associées aux ANCA : GW, MPA et formes rénales limitées (glomérulonéphrite pauci-immune), avec ou sans ANCA (au diagnostic comme à la rémission).
 
 
2005-005217-38: Randomiseret forsøg der sammenligner 4 og 6 kemoterapicykler med CHOP (Cyklofosfamid, Doxorubicin, Vincristin og Prednison) i 21-dages intervaller, begge med 6 cykler immunterapi med monoklonalt anti-CD20-antistof-rituximab, hos patienter med aggressiv CD20-positivt B-celle-lymfom i alderen 18 til 60 år uden risikofaktor (aldersjusteret IPI=0) og uden massiv sygdom (diameter < 7,5cm) Kort titel: FLYER 6-6/6-4-forsøg

Ongoing
3
200
Europe
MabThera, cyclophosphamid, Doxorubicin, vincristne, prednison, MabThera(rituximab), Cyclophosphamid \"A-Pharma\", Doxorubicin, Vincristine, Prednison \"DAK\", MabThera(rituximab), Cyclophosphamid \"A-Pharma\", Doxorubicin, Vincristine, Prednison \"DAK\"
German High Grade Non-Hodgkins Lymphoma group, German High-Grade non- Hodgkin\'s Lynphoma Study Group
Patients with untreated aggressive CD20+ Non-Hodgkin’s Lymphoma aged 18 to 60 years without major accompanying disorders with no risk factor according to IPI and no bulky disease (<7,5cm)
 
 
2005-005918-20: Rituximab as second line treatment for ITP:A Multicentre, Randomized, Double blind,Placebo-controlled, Phase III study.“The RITP study”

Ongoing
3
30
Europe
MabThera, MabThera®, MabThera®
Rikshospitalet, Sykehuset Østfold, Fredrikstad
Immune thrombocytopenic purpura (ITP).
 
 
2009-009178-28: Etude ouverte, randomisée, comparant l\'efficacité du retraitement par etanercept ou par rituximab, après insuffisance d\'efficacité du rituximab, chez les patients atteints de polyarthrite rhumatoïde active

Ongoing
3
110
Europe
rituximab, etanercept, methotrexate, Mabthera, Enbrel, Mabthera, Enbrel
CHRU Montpellier- Direction de la Recherche, Partenariats et Réseaux, Relations avec l\'Université
acute rhumatoid polyarthritis
 
 
2009-016136-12: PET-RIMCEB:Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patientsA phase III studyA randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas+A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas

Ongoing
3
150
Europe
Mabthera, Mabthera, Mabthera
Czech Lymphoma Research Organization s.r.o. (CLRO)
Prognosis of high-risk patients with diffuse large B-cell lymphoma is still less then optimal. According to revised Int. Prognostic Index, patients with 3-5 adverse prognostic factors have only about 50% chance of survival in 4 years. In theory, there are 3 possibilities how to improve prognosis of patients with poor-risk DLBCL: intensification of induction therapy, high-dose consolidation treatment with autologous stem cell transplant or combination of both methods.
 
 
2009-014722-42: Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study

Ongoing
3
140
Europe
Rituximab, Mabthera, Mabthera
HOVON Foundation, Dutch Cancer Foundation (KWF)
Primary Central Nervous system Lymphoma
 
 
2011-004171-36: A study comparing SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthritis (RA)

 
3
50
Europe
SAIT101, MabThera®, SAIT101, MabThera®, MabThera®
Samsung Electronics Co. Ltd., Samsung Electronics Co. Ltd.
Severe Rheumatoid Arthritis (RA)
 
06/13
2013-005506-56: The comparative clinical trial with use of two biologic products: MabionCD20 and MabThera in lymphoma patients

Ongoing
3
30
Europe, RoW
MabionCD20 (biosimilar to rituximab), MabThera, CD20, MabThera, MabThera
MABION SA, Mabion SA, Mabion SA
CD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance at least 6 months
 
 
2012-001980-53: Low doses of Rituximab in Graves orbitopathy Bassa dose di Rituximab nell\'orbitopatia basedowiana

Ongoing
3
10
Europe
MABTHERA*EV 2F 10ML 100MG, MABTHERA*EV 2F 10ML 100MG
FONDAZIONE IRCCS CA\' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Active moderate to severe Graves Orbitopathy Orbitopatia basedowiana attiva moderata-severa
 
 
2014-001363-12: Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

Ongoing
3
870
Europe, RoW
Ibrutinib, PCI-32765, Capsule, hard, Imbruvica
Klinikum der Universität München, Medizinische Klinik und Poliklinik III, HOVON Foundation, KroHem, Janssen Pharmaceutica NV, Skåne University Hospital, Department of Oncology, Dutch Cancer Society
Generalized mantle cell Lymphoma, Generalized mantle cell Lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ACTRN12610000908033: Rituximab in Primary Central Nervous system Lymphoma. A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

Active, not recruiting
3
80
 
HOVON, Roche Products Pty Ltd
primary central nervous system (CNS) lymphoma
 
 
ChiCTR2200055579: The Effect of Chinese Patent Medicine Pai-Neng-Da Capsule Combination with Chemotherapy on Peripheral Blood Cell Count and Symptoms of Patients with B Cell non-Hodgkin’s Lymphoma:A Clinical Multi-Center Study

Completed
3
100
 
R-CHOP-21 scheme + Pai-Neng-Da Capsule ;R-CHOP-21 scheme
Lishui Central Municiple Hospital; Lishui Central Municiple Hospital, Administration of Traditional Chinese medicine of Zhejiang Province
cell non-Hodgkin’s lymphoma
 
 
2016-004010-10: A Phase 3 evaluation of how PET scans can help guide further therapy or no therapy for patients with previously untreated, high tumour burden follicular lymphoma

Ongoing
3
840
Europe
Rituximab (for intravenous infusion), Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg), Concentrate for solution for infusion, Capsule, hard, Solution for injection, Revlimid (2.5mg), MabThera (1400 mg solution for subcutaneous injection), Revlimid (5mg), Revlimid (10mg), Revlimid (15mg), Revlimid (20mg)
University of Liverpool, Cancer Research UK
Previously untreated, high tumour burden follicular lymphoma, Follicular lymphoma is a cancer of the immune system. The cancerous cells accumulate mainly in lymph glands which become swollen. It is incurable and therefore requirement multiple lines of treatment., Diseases [C] - Cancer [C04]
 
 
2017-000390-37: Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

Not yet recruiting
3
136
Europe
Coated tablet, Solution for injection, Tablet, Imurel 25 mg, MABTHERA 100mg, Cellcept, Cortancyl
Centre Hospitalier Départemental Vendée de la Roche sur Yon, Centre Hospitalier Départemental Vendée
End-stage renal diseaseANCA vascularitisImmunosuppressive therapy, End-stage renal diseaseANCA vascularitisImmunosuppressive therapy, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
2017-002290-19: Rituximab maintenance will be compared to “lenalidomide plus rituximab maintenance followed by lenalidomide only maintenance” for relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Not yet recruiting
3
450
Europe
Capsule, hard, Concentrate for solution for infusion, Revlimid 2.5mg, hard capsules, Revlimid 5mg, hard capsules, Revlimid 10mg, hard capsules, Revlimid 15mg, hard capsules, Revlimid 20.0 mg, hard capsules, MabThera 500mg, concentrate for solution for infusion
Celgene Corporation, Celgene Corporation
relapsed/refractory follicular, marginal zone or mantle cell lymphoma, Three types of blood cancer called lymphoma, Diseases [C] - Cancer [C04]
 
 
2016-002272-27: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy.

Ongoing
3
388
Europe
Opdivo, Solution for injection, Opdivo
Saarland University, Bristol-Myers Squibb
Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ChiCTR-TRC-08000243: A Prospective, Multicenter, Randomized Phase III Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients

Recruiting
3
732
 
CHOP combined with Rituximab regimen (R-CHOP21) ;Biweekly CHOP combined with Rituximab regimen (R-CHOP14) ;Biweekly CHOP regimen (CHOP14)
Sun Yat-sen University; Level of the institution：, Sun Yat-sen University
untreated CD20 positive difussed large B cell lymphoma adults
 
 
2017-002602-12: Improving Transplant Opportunities for Patients who are Sensitised (ITOPS)

Not yet recruiting
3
38
Europe
Rituximab, Bortezomib, Dexamethasone, Solution for infusion, Powder for injection, Tablet, Rituximab, Bortezomib, Dexamethasone
Cardiff and Vale University Health Board, Kidney Research UK
Highly Sensitised Patients(patients with high levels of human leucocyte antigen specific antibodies) awaiting renal transplantation.These patients are difficult to match to a compatible donor and thus rates of transplantation are low., Highly sensitised patients are difficult to transplant due to the risk of rejection. They may not be able to receive a kidney directly from their living donor, and may wait a long time for transplant., Diseases [C] - Immune System Diseases [C20]
 
 
2017-004079-30: Stratification of biologic Therapies for Rheumatoid Arthritis by Pathobiology

Ongoing
3
219
Europe
MabThera, RoActmera, Enbrel, Concentrate for solution for infusion, Solution for injection, Solution for injection in pre-filled pen, MabThera, RoActmera, Enbrel
Joint Research & Development Office (QMUL), AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Medical Research Council, Arthritis Research UK, Queen Mary University of London (QMUL)
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-005034-36: Study evaluating the effect of rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Studio che valuta l'effetto del farmaco rituximab nei pazienti con poliradicoloneuropatia cronica infiammatoria demielinizzante (CIDP) in trattamento cronico con immunoglobuline

Ongoing
3
60
Europe
Rituximab, Paracetamolo, Metilprednisolone sodio succinato, Clorfenamina maleato, [Rituximab], [Paracetamolo], [Metilprednisolone sodio succinato], [Clorfenamina maleato], Concentrate for solution for infusion, Tablet, Powder and solvent for solution for injection, Solution for injection, MABTHERA - 1 FIALA 500 MG 50 ML, TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE, SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML, TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML
IRCCS ISTITUTO CLINICO HUMANITAS, AIFA - Italian Medicines Agency
Chronic inflammatory demyelinating polyradiculoneuropathy Poliradicoloneuropatia cronica infiammatoria demielinizzante, Chronic inflammatory demyelinating polyradiculoneuropathy Polineuropatia cronica infiammatoria demielinizzante, Diseases [C] - Nervous System Diseases [C10]
 
 
ALLIANCE A041202, NCT01886872: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Ibrutinib + Rituxan for 1L CLL
Dec 2018 - Dec 2018: Ibrutinib + Rituxan for 1L CLL
Active, not recruiting
3
547
Canada, US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/18
01/25
ECOG-ACRIN E1912, NCT02048813: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Checkmark From E1912 study in combination with rituximab for 1L CLL
Dec 2019 - Dec 2019: From E1912 study in combination with rituximab for 1L CLL
Checkmark Ibrutinib + Rituxan for 1L CLL
Dec 2018 - Dec 2018: Ibrutinib + Rituxan for 1L CLL
Active, not recruiting
3
529
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/18
12/24
NCT01788020 / 2013-000506-37: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Completed
3
202
Europe
Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
University of Ulm, Centre Hospitalier de Lens (Co-Sponsor)
Waldenström's Macroglobulinemia
11/18
04/24
2018-002632-24: to evaluate a triple therapy: plasma exchange, rituximab, intravenous immunoglobulin (IVIg) and corticosteroid administration compared to standard corticosteroid therapy in patients for severe acute exacerbation of idiopathic pulmonary Evaluer l'impact sur la mortalité globale au 28ème jour après le début des échanges plasmatiques, rituximab, immunoglobulines intraveineuses (IVIg) et l’administration de corticoïdes par rapport à la corticothérapie standard chez les patients pour l’exacerbation aiguë sévère de fibrose pulmonaire idiopathique

Not yet recruiting
3
40
Europe
Concentrate for solution for infusion, Solution for infusion, , RIXATHON 500 mg, PRIVIGEN 100mg/ml
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), APHP
severe acute exacerbation of idiopathic pulmonary fibrosis Exacerbation aiguë de Fibrose Pulmonaire Idipatique, idiopathic pulmonary fibrosis Fibrose Pulmonaire Idipatique, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
ChiCTR-TRC-11001687: A prospective, multicenter randomized phase III clinical trial of intensified chemotherapy in improving the treatment efficacy of patient with diffuse large B-cell lymphoma

Recruiting
3
454
 
R-CHOP repeated in 21 days ;R-CHOP repeated in 14 days
SUN YAT-SEN UNIVERSITY CANCER CENTER; SUN YAT-SEN UNIVERSITY CANCER CENTER, SUN YAT-SEN UNIVERSITY CANCER CENTER/SUN YAT-SEN UNIVERSITY
Diffuse large B-cell Lymphoma
 
 
2018-003842-18: Gene therapy study using a frozen formulation of OTL-103 in patients with Wiskott-Aldrich Syndrome (WAS) Studio con terapia genica che utilizza una formulazione congelata di OTL-103 in pazienti con sindrome di Wiskott-Aldrich (WAS).

Not yet recruiting
3
6
Europe
OTL-103 Dispersion for Infusion, granulocyte colony stimulating factor (G-CSF), OTL-103, Dispersion for infusion, Concentrate for solution for infusion, Solution for injection, Powder and solvent for solution for injection, Busilvex, Fludarabina Accord, MabThera, Mozobil,, MYELOSTIM
Orchard Therapeutics Ltd., Orchard Therapeutics Ltd
Wiskott-Aldrich Syndrome Sindrome di Wiskott-Aldrich, A rare genetic disease characterized by immune deficiency rara malattia genetica caratterizzata da deficit immunitario, Diseases [C] - Immune System Diseases [C20]
 
 
CIDPRIT, NCT06325943: Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed
3
37
Europe
Rituximab, Placebo
Istituto Clinico Humanitas, Ospedale Mondino di Pavia, University of Turin, Italy, Istituto Neurologico Carlo Besta di Milano, San Raffaele University Hospital, Italy, Università di Messina, Universita degli Studi di Genova, Istituto Di Ricerche Farmacologiche Mario Negri, Università di Napoli Federico II
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
05/23
11/23
NCT02414022: Economic Analysis of Alliance A041202 CLL Study

Checkmark Presentation of data from Alliance A041202 CLL study for CLL at ASH 2018
Dec 2018 - Dec 2018: Presentation of data from Alliance A041202 CLL study for CLL at ASH 2018
Active, not recruiting
3
55
Canada
Canadian Cancer Trials Group
Chronic Lymphocytic Leukemia
04/19
01/25
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
2018-004611-50: The Use of Rituximab IN treatment of immune-mediated Glomerulonephritis (TURING)

Not yet recruiting
3
112
Europe
Rituximab, Concentrate for solution for infusion
Cambridge University Hospitals NHS Foundation Trust, NIHR HTA
Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS), These are auto-immune renal diseases that present with a common clinical phenotype, the nephrotic syndrome (NS).
 
 
2019-001505-24: A Clinical Study Comparing Rituximab and Cladribine for Relapsing Remitting Multiple Sclerosis

Ongoing
3
266
Europe
Rituximab, Cladribine, Concentrate for solution for infusion, Tablet, Rixathon konsentrat til infusjonsvaeske oppløsning 10 mg/ml, Mavenclad tabletter 10 mg
Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital
Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis (MS), Diseases [C] - Nervous System Diseases [C10]
 
 
2019-002542-20: Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligne Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligne

Not yet recruiting
3
36
Europe
Prevenar13®, Pneumovax®, Solution for injection, Prevenar13®, Pneumovax®
CHRU de TOURS, CHRU de TOURS
Patients atteints de lymphome diffus à grandes cellules B Patients atteints de lymphome diffus à grandes cellules B, Patients atteints de lymphome diffus à grandes cellules B Patients atteints de lymphome diffus à grandes cellules B, Diseases [C] - Cancer [C04]
 
 
ChiCTR-IIR-16008400: The efficientcy of cyclophosphamide plus dexamethasone combinated with rituximab or bortezomib for the newly diagnosed lymphoplasmacytic lymphoma / Waldenstr?m macroglobulinemia - a Prospective Multicentre Randomized control Trial from China

Recruiting
3
110
 
BCD regimen ;RCD regimen
Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College; Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, State Science Technology Project from China
lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation

Checkmark Data from REACH3 trial for acute GVHD at ASH 2020
Dec 2020 - Dec 2020: Data from REACH3 trial for acute GVHD at ASH 2020
Checkmark Data from REACH3 trial in steroid-refractory chronic GVHD
Jul 2020 - Jul 2020: Data from REACH3 trial in steroid-refractory chronic GVHD
Completed
3
330
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Incyte Corporation
Graft-versus-host Disease (GVHD)
05/20
12/22
2020-000736-21: A Phase 3 study to evaluate the efficacy and safety of HLX01 versus rituximab (Mabthera®) as treatment for patients with low tumour burden follicular lymphoma.

Not yet recruiting
3
212
Europe
Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection, Mabthera®, HLX01, Concentrate for solution for infusion, Mabthera®
Shanghai Henlius Biotech Inc., Shanghai Henlius Biotech, Inc.
Low tumour burden follicular lymphoma, Disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-001205-23: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease

Not yet recruiting
3
211
Europe
Ocrelizumab, Rituximab, Concentrate for solution for infusion, Ocrevus, Rituximab
Helse Bergen HF, Haukeland University Hospital, Program for klinisk behandlingsforskning i spesialisthelsetjenesten (KLINBEFORSK)
Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
CHRONOS-3, NCT02367040 / 2013-003893-29: Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Checkmark Data from CHRONOS-3 trial in combination with rituximab for refractory indolent MZL at ESMO 2021
Jul 2021 - Jul 2021: Data from CHRONOS-3 trial in combination with rituximab for refractory indolent MZL at ESMO 2021
Checkmark Filing of sNDA in combination with rituximab for indolent B-cell non-Hodgkin’s Lymphoma
Jun 2021 - Jun 2021: Filing of sNDA in combination with rituximab for indolent B-cell non-Hodgkin’s Lymphoma
Checkmark Submission MAA to the EMA in combination with rituximab for MZL
More
Active, not recruiting
3
458
Europe, Japan, US, RoW
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Bayer
Lymphoma,Non-Hodgkin
08/20
11/24
NCT03650933: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients

Recruiting
3
360
RoW
G-CHOP, R-CHOP
Nanjing Yoko Biomedical Co., Ltd.
Diffuse Large B-Cell Lymphoma, Unspecified Site
08/22
12/25
2019-001755-39: A Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.

Ongoing
3
600
Europe
acalabrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, ACP-196, L01X C02, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection, Solution for infusion, Solution for injection, Tablet, MabThera 500 mg concentrate for solution for infusion, Endoxan 500 mg Powder for solution for injection, Ribodoxo 2 mg/ml solution for infusion, Vincristinesulfat-TEVA 1 mg/ml Injectable solution, Prednisone HEXAL 20 mg tablets
Acerta Pharma B.V. (A Member of the AstraZeneca Group), ACERTA PHARMA BV, AstraZeneca
Diffuse large B-cell lymphoma, A type of non-Hodgkin lymphoma that develops when B-cells become abnormal., Diseases [C] - Cancer [C04]
 
 
NCT03501459: Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome

Recruiting
3
100
RoW
Rituximab
National University Health System, Singapore
Nephrotic Syndrome
12/20
12/25
2020-002981-15: Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis.

Not yet recruiting
3
594
Europe
Concentrate for solution for infusion, Ocrevus, Ruxience
Danish Multiple Sclerosis Center, Rigshospitalet, Danish Regions
Multiple sclerosis., Multiple sclerosis., Diseases [C] - Nervous System Diseases [C10]
 
 
2020-000729-13: Evaluation of Glucocorticoids plus Rituximab compared to Glucocorticoids plus Placebo for the treatment of patients with newly-diagnosed or relapsing IgA vasculitis Evaluation des corticoïdes en association à un traitement par RITUXIMAB versus corticoïdes et placebo pour l’induction de la rémission au cours des vascularites à IgA sévères de l’adulte (purpura rhumatoïde), au diagnostic ou en rechute.

Ongoing
3
72
Europe
RituxiMab, Injection, RituxiMab (MabThera)
Hôpital Foch, DRCI Hôpital Foch
Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV. Patients avec un diagnostic de vascularite à IgA (IgAV) selon les définitions de la Conférence de consensus de Chapel Hill. Les patients devront avoir un diagnostic d’IgAV prouvé par biopsie., Patients with a diagnosis of IgAV Patients avec un diagnostic de vascularite à IgA (IgAV), Diseases [C] - Immune System Diseases [C20]
 
 
2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-5)

Ongoing
3
350
Europe, RoW
Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin, ADCT-402, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, TRUXIMA, Bendacitabin 38 mg/ml, Oxali-Bendalis 5 mg/ml
ADC Therapeutics SA, ADC THERAPEUTICS SA, ADC Therapeutics SA
Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma, Diseases [C] - Cancer [C04]
 
 
2021-000009-25: Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study Traitement par Rituximab de patients avec neuropathie anti-MAG et facteurs de bonne réponse: l’étude THERAMAG

Not yet recruiting
3
90
Europe
MabThera, Solution for infusion, Rituximab
CHU SAINT-ETIENNE, CHU SAINT-ETIENNE
Anti-MAG neuropathy neuropathie anti-MAG, Anti-MAG neuropathy neuropathie anti-MAG, Diseases [C] - Nervous System Diseases [C10]
 
 
2018-002115-96: Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and total drug dose in comparison to the standard induction therapy and both treatments followed by a high dose therapy with autologous stem cell transplantation. The therapy is for patients with newly diagnosed primary lymphoma of the central nervous system. Optimierung einer in Dauer und Gesamtdosis abgeschwächten, einleitenden Therapie mit MATRix, einer Medikamentenkombination, bestehend aus Methotrexat, ARA-C, Thiotepa und Rituximab im Vergleich zur Standard Einleitungstherapie; beiden folgt eine Hochdosistherapie und autologe Stammzelltransplantation. Die Behandlung ist für Patienten mit neu diagnostizierten primären Lymphomen des zentralen Nervensystems.

Not yet recruiting
3
326
Europe
Rituximab, Methotrexate, Cytarabine, Thiotepa, Carmustine, Busulfan, [NA], Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Powder and solvent for solution for infusion
Klinikum Stuttgart, Landeshauptstadt Stuttgart gKAöR, CITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART, BMBF Federal Ministry of Education and Research, Dipartimento Federale della Formazione e della Ricerca (BMBF/DLR)
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is a rare disorder confined to the cerebral parenchyma, leptomeninges, eyes or spinal cord. It accounts for 4 to 6% of all Non-Hodgkin’s lymphomas and for 3 to 4% of all primary brain tumors. Incidence of PCNSL has increased over the past 30 years, particularly in immunocompetent individuals.With a median survival of 3 months in untreated individuals, prognosis of PCNSL resembles that of systemic high-grade NHL. Primäres diffuses großes B-Zell-Lymphom (DLBCL) des zentralen Nervensystems ist eine seltene Erkrankung der zerebalen Parenchyma, Leptomeninges, der Augen oder des Rückenmarks. Sie macht 4-6% aller Non-Hodgkin Lymphome (NHL) und 3-4% aller primären Hirntumore aus. Die Inzidenz von PZNSL ist in den vergangenen 30 Jahren angestiegen vor allem bei immunkompeten Patienten. Die durchschnittliche Überlebensrate bei unbehandelten Patienten liegt bei 3 Monaten., Primary diffuse large B-cell lymphoma of central nervous system, a rare disorder confined to the brain and spinal cord. The disease may be fatal within a short period of time when remained untreated. ZNSNHL ist eine seltene Erkrankung des lymphat. Systems im Bereich Gehirn/Rückenmark. Es handelt sich dabei um bösartiger Immunzellen. Die Krankheit kann unbehandelt in kurzer Zeit zum Tode führen., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
2019-002962-10: An unblinded study to compare the treatment success and tolerability of a chemotherapy consisting of a combination of rituximab, ifosfamide, carboplatin and etoposide with and without the addition of polatuzumab vedotin in subject suffering from an aggressive lymphoma, a malignant disease of the lymphatic system.

Not yet recruiting
3
334
Europe
Polivy, Mabthera, Ifosfamide, Carboplatin, Etoposide, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Polivy, MABTHERA®
GWT-TUD GmbH, F. Hoffmann-La Roche Ltd
primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), patients whose cancer of the lymph nodes has returned or not responded to treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
2020-004982-37: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome Wczesne leczenie rituximabem dzieci z idiopatycznym zespołem nerczycowym Ang. ERICONS – Early RITUXIMAB in Childhood Onset Nephrotic Syndrome

Not yet recruiting
3
60
Europe
MabThera 100mg concentrate for solution for infusion, MabThera 500mg concentrate for solution for infusion, Concentrate for solution for infusion, MabThera 100mg, concentrate for solution for infusion, MabThera 500mg concentrate for solution for infusion
MEDICAL UNIVERSITY OF GDAŃSK, Medical Research Agency
NEPHROTIC SYNDROME IDIOPATYCZNY ZESPÓŁ NERCZYCOWY, NEPHROTIC SYNDROME IDIOPATYCZNY ZESPÓŁ NERCZYCOWY, Diseases [C] - Symptoms and general pathology [C23]
 
 
NCT02035462 / 2009-012476-28: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
3
787
US, Canada, Europe, RoW
RO5072759, rituximab, chlorambucil
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., , F.Hoffmann-La Roche Ltd.
Lymphocytic Leukemia, Chronic
06/21
06/21
2020-004554-30: A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab

Ongoing
3
250
Europe, RoW
LOXO-305, Bendamustine Hydrochloride, Rituximab, Idelalisib, [na], Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Bendamustine Accord, Bendamustin cell pharm®, MabThera, Zydelig
Loxo Oncology Inc, LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years., Diseases [C] - Cancer [C04]
 
 
2020-005619-35: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-ANTIBODY POSITIVE MYASTHENIA GRAVIS Fenotipizzazione dei linfociti B con studio della singola cellula per la personalizzazione dell’immunoterapia in pazienti con Miastenia Gravis: studio clinico randomizzato controllato contro placebo per valutare l’efficacia e la sicurezza del Rituximab in pazienti con Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina

Ongoing
3
40
Europe
rituximab, [rituximab], Concentrate for solution for infusion
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Ministero della Salute
Generalized AChR-antibody positive Myasthenia Gravis Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina, generalized AChR-antibody positive Myasthenia Gravis Miastenia Gravis generalizzata associata ad anticorpi anti-recettore dell’Acetilcolina, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-000492-21: Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in adult EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant lymphoproliferative disorders Étude prospective multicentrique randomisée évaluant l’efficacité d’un traitement préventif par Rituximab chez des adultes patients transplantés rénaux EBV négatifs sur l’incidence de la primoinfection EBV et des syndromes lymphoprolifératifs

Not yet recruiting
3
120
Europe
Rituximab, Concentrate for solution for infusion
Les Hôpitaux Universitaires de Strasbourg, Les Hôpitaux Universitaires de Strasbourg
Kidney transplantation Epstein Barr virus Transplantation rénale et virus Epstein Barr, Kidney transplantation Epstein Barr virus Transplantation rénale et virus Epstein Barr, Diseases [C] - Virus Diseases [C02]
 
 
SHINE , NCT01776840 / 2012-004056-11: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark Data from SHINE trial in 1L MCL at ASCO 2022
Jun 2022 - Jun 2022: Data from SHINE trial in 1L MCL at ASCO 2022
Checkmark From SHINE trial in 1L MCL
Mar 2022 - Mar 2022: From SHINE trial in 1L MCL
Completed
3
523
Europe, Canada, Japan, US, RoW
Bendamustine, Rituximab, Ibrutinib, Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
06/21
06/24
EVAPOR, NCT04214444: Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab

Recruiting
3
36
Europe
Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
University Hospital, Tours, Hôpital Cochin
Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
07/21
07/22
ASCEND, NCT02970318 / 2015-004454-17: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Checkmark 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Checkmark From ASCEND trial for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From ASCEND trial for r/r CLL at ASH 2021
Checkmark From ASCEND trial for r/r CLL at EHA 2020
More
Active, not recruiting
3
310
Europe, Canada, US, RoW
Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/21
10/27
2020-003277-22: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with Follicular Lymphoma Immunochemioterapia standard vs immunoterapia standard e chemioterapia a ridotto numero di cicli per il trattamento in prima linea di pazienti con Linfoma Follicolare

Not yet recruiting
3
602
Europe
Ciclofosfamide, Rituximab, Bendamustina, Doxorubicina, Prednisone, Vincristina, Obinutuzumab, [IMP4], [IMP1], [IMP3], [IMP2], [IMP5], [IMP8], [IMP7], [IMP6], , Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Concentrate and solvent for solution for infusion, Tablet, Solution for injection, ENDOXAN BAXTER - 200 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONI VETRO TIPO III 200 MG, MABTHERA - 1 FIALA 500 MG 50 ML, LEVACT - 2.5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE 5 FLACONCINI IN VETRO DA 100 MG, MABTHERA - 1400 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 15 ML (120MG/ML) - 1 FLACONCINO, DOXORUBICINA TEVA - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10MG/5ML, PREDNISONE DOC GENERICI - "25 MG COMPRESSE" 10 COMPRESSE IN BLISTER PVC-PVDC/ALU, VINCRISTINA TEVA ITALIA - 1 MG/ML SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO DA 5 ML, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, FONDAZIONE GRADE ONLUS
High tumor burden Follicular Lymphoma Linfoma Follicolare ad elevato carico tumorale., High tumor burden Follicular Lymphoma. Linfoma Follicolare ad elevato carico tumorale., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-001234-20: A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Studio di fase 3 che confronta Pirtobrutinib (LOXO-305) con Bendamustina più Rituximab in pazienti con LLC/SLLnon trattati

Not yet recruiting
3
250
Europe, RoW
Rituximab, Bendamustine Hydrochloride, Pirtobrutinib, [na], [LOXO-305], Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Film-coated tablet, MabThera, Bendamustina Accord, Bendamustin cell pharm®
LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Leucemia linfatica cronica (LLC)/linfoma linfocitico a piccole cellule, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years. La leucemia linfatica cronica (LLC)/il linfoma linfocitico a piccole cellule (SLL) è un tipo di tumore che colpisce i globuli bianchi e tende a progredire lentamente nell’arco di molti anni., Diseases [C] - Cancer [C04]
 
 
NCT02320292: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Completed
3
20
US
Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Yttrium Y-90 Ibritumomab Tiuxetan, IDEC-Y2B8, IDEC-Y2B8 monoclonal antibody, Y 90 Ibritumomab Tiuxetan, Y 90 Zevalin, Yttrium Y 90 Ibritumomab Tiuxetan, yttrium Y90 ibritumomab tiuxetan
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
02/21
11/23
2021-000006-16: NA NA

Not yet recruiting
3
132
Europe
Bélimumab, Solution for injection in pre-filled syringe, BENLYSTA
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Laboratoire GSK France
Adults with a definite diagnosis of primary chronic immune thrombocytopeniaaccording to the standard definition. Patients with antinuclear antibodies with no definite criteria for systemic lupus will be eligible., adult patients with persistent or chronic immune thrombocytopenia (ITP), Diseases [C] - Immune System Diseases [C20]
 
 
2021-000362-15: Therapy of follicular lymphoma with radiotherapy an antibody

Not yet recruiting
3
130
Europe
Concentrate for solution for infusion, GAZYVARO, MabThera
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial, Roche Pharma AG, Department of Radiation Oncology, Universityhospital Heidelberg
nodal follicular lymphoma grade 1 or grade 2 in the clinical stage I or II (Ann Arbor classification), nodal follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ChiCTR2000032550: A prospective randomized phase III clinical trail of aggressive field helical tomography (TOMO) combined with rituximab versus rituximab in stage III follicular lymphoma with complete remission

Recruiting
3
158
 
RTX 375 mg/m2, eight week once, total 12 times + aggressive field TOMO radiotherapy ;RTX 375 mg/m2, eight week once, total 12 times
Sun Yat-sen Uncersity Cancer Center; Sun Yat-sen Uncersity Cancer Center, None
Follicular lymphoma
 
 
SELENE , NCT01974440 / 2013-003093-27: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Hourglass Jul 2022 - Dec 2022 : Data from SELENE trial for follicular lymphoma/MZL
Completed
3
403
Europe, Japan, US, RoW
Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma
05/22
06/23
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
06/22
06/27
IELSG37, NCT01599559: Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
3
540
Europe, Canada, US, RoW
observation, 3D-Conformal Radiotherapy (3D-CRT)
International Extranodal Lymphoma Study Group (IELSG)
Primary Mediastinal B-cell Lymphoma
06/22
12/29
NCT05332587: Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

Recruiting
3
50
RoW
Rituximab
First Affiliated Hospital, Sun Yat-Sen University
Refractory Myasthenia Gravis, Rituximab
07/22
07/22
2021-003260-28: A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular Lymphoma Uno studio che valuta l’efficacia di axicabtagene ciloleucel rispetto alla terapia standard di cura in soggetti con linfoma follicolare recidivante/refrattario

Not yet recruiting
3
230
Europe
Bendamustine hydrochloride, Rituximab, Cyclophosphamide, Lenalidomide, Vincristine, Doxorubicin, Prednisolone, axicabtagene ciloleucel, [na], [KTE-C19], , Concentrate and solvent for concentrate for solution for infusion, Powder for concentrate for solution for infusion, Capsule, hard, Concentrate for solution for injection/infusion, Powder and solvent for concentrate for solution for infusion, Soluble tablet, Dispersion for infusion, Bendamustine 100 mg Powder for Concentrate for Solution for Infusion, MabThera, Endoxana Injection 1000 mg Powder for Solution for Injection, Revlimid, Vincristine Sulfate 1mg/ml Solution for Injection or Infusion, Doxorubicin 50 mg Powder for Concentrate for Solution for Infusion, Prednisolone, Yescarta
KITE PHARMA INC., Kite Pharma, Inc., Kite Pharma, Inc.
Relapsed and/or Refractory Follicular Lymphoma Linfoma follicolare recidivante e/o refrattario, Cancer that forms in white blood cells that has come back or has been resistant to previous therapies Cancro che si forma nei globuli bianchi che è ritornato o che è resistente alle terapie precedenti, Diseases [C] - Cancer [C04]
 
 
GMALL, NCT02881086 / 2013-003466-13: Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Active, not recruiting
3
1000
Europe
Rituximab, Nelarabine, PEG-Asparaginase, Cranial irradiation, Imatinib, Idarubicin, Dexamethasone, Cyclophosphamide, Fludarabine, Vincristine, Mercaptopurine, VP16, Daunorubicin (DNR), Methotrexate, Stem cell transplantation, Cytarabine, Vindesine, Adriamycin, Prednisolone
Goethe University
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
08/22
07/25
2022-002385-32: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomized controlled clinical trial Traitement immédiat versus retardé par azathioprine ou rituximab dans les maladies démyélinisantes associées aux anticorps anti-myéline oligodendrocytes glycoprotéine (anti-MOG) chez l'enfant : un essai clinique contrôlé randomisé

Not yet recruiting
3
86
Europe
azathioprine, RIXATHON®, méthylprednisolone, prednisolone, Coated tablet, Concentrate for solution for infusion, Powder for solution for injection, Tablet, IMUREL 25 mg, RIXATHON, méthylprednisolone, Prednisolone, AZATHIOPRINE EG 50mg
Assistance Publique – Hôpitaux de Paris (AP-HP), ministère de la santé (DGOS)
myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD) maladies démyélinisantes associées aux anticorps anti-myéline oligodendrocyte glycoprotéine (MOG)., myelin oligodendrocytes glycoprotein antibody associated diseases maladies démyélinisantes associées aux anticorps anti-myéline oligodendrocyte glycoprotéine, Diseases [C] - Nervous System Diseases [C10]
 
 
 

Download Options